Allogene Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
David Chang
Chief executive officer
US$14.1m
Total compensation
CEO salary percentage | 5.1% |
CEO tenure | 6yrs |
CEO ownership | 3.7% |
Management average tenure | 1.3yrs |
Board average tenure | 6.2yrs |
Recent management updates
Recent updates
Allogene: Two End Of 2024 Data Readouts With Improved Allogeneic CAR-T Products
Jun 12We Discuss Why Allogene Therapeutics, Inc.'s (NASDAQ:ALLO) CEO Compensation May Be Closely Reviewed
May 30Allogene Therapeutics: 2024 Platform Vision Sings Mid-Term Upside
Apr 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Mar 01We Think Allogene Therapeutics (NASDAQ:ALLO) Needs To Drive Business Growth Carefully
Jun 09We're Hopeful That Allogene Therapeutics (NASDAQ:ALLO) Will Use Its Cash Wisely
Feb 22Allogene Therapeutics (NASDAQ:ALLO) Is In A Good Position To Deliver On Growth Plans
Oct 27Allogene begins phase 2 allogeneic CAR T trial for large B-cell lymphoma candidate
Oct 06An Intrinsic Calculation For Allogene Therapeutics, Inc. (NASDAQ:ALLO) Suggests It's 23% Undervalued
Sep 22Allogene: Possible First Pivotal Study With Allogeneic CAR-T ALLO-501A
Sep 13Allogene Therapeutics GAAP EPS of -$0.52 beats by $0.08, revenue of $0.09M beats by $0.07M
Aug 09Companies Like Allogene Therapeutics (NASDAQ:ALLO) Are In A Position To Invest In Growth
Jul 14Allogene Therapeutics: Multibagger Potential, But Terribly Risky
Jun 24Allogene: Leading The Allogeneic CAR-T Space, Again
Apr 01Allogene: Lifting Of The Clinical Hold Will Be A Major Binary
Jan 12CEO Compensation Analysis
Date | Total Compensation | Salary | Company Earnings |
---|---|---|---|
Mar 31 2024 | n/a | n/a | -US$292m |
Dec 31 2023 | US$14m | US$724k | -US$327m |
Sep 30 2023 | n/a | n/a | -US$342m |
Jun 30 2023 | n/a | n/a | -US$364m |
Mar 31 2023 | n/a | n/a | -US$361m |
Dec 31 2022 | US$15m | US$724k | -US$340m |
Sep 30 2022 | n/a | n/a | -US$313m |
Jun 30 2022 | n/a | n/a | -US$308m |
Mar 31 2022 | n/a | n/a | -US$304m |
Dec 31 2021 | US$10m | US$695k | -US$182m |
Sep 30 2021 | n/a | n/a | -US$251m |
Jun 30 2021 | n/a | n/a | -US$239m |
Mar 31 2021 | n/a | n/a | -US$229m |
Dec 31 2020 | US$8m | US$675k | -US$316m |
Sep 30 2020 | n/a | n/a | -US$243m |
Jun 30 2020 | n/a | n/a | -US$227m |
Mar 31 2020 | n/a | n/a | -US$207m |
Dec 31 2019 | US$11m | US$600k | -US$185m |
Sep 30 2019 | n/a | n/a | -US$154m |
Jun 30 2019 | n/a | n/a | -US$147m |
Mar 31 2019 | n/a | n/a | -US$240m |
Dec 31 2018 | US$13m | US$362k | -US$212m |
Compensation vs Market: David's total compensation ($USD14.06M) is above average for companies of similar size in the US market ($USD2.43M).
Compensation vs Earnings: David's compensation has been consistent with company performance over the past year.
CEO
David Chang (64 yo)
6yrs
Tenure
US$14,061,848
Compensation
Dr. David D. Chang, M.D., Ph.D. is the President, Chief Executive Officer and Director of Allogene Therapeutics, Inc since June 2018. He served as Chief Medical Officer and Executive Vice President of Rese...
Leadership Team
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder & Executive Chairman | 6.6yrs | US$9.36m | 2.94% $ 14.3m | |
Co-Founder | 6yrs | US$14.06m | 3.7% $ 18.0m | |
Co-Founder & Director | no data | US$684.49k | 0.15% $ 706.2k | |
Executive VP & Chief Technical Officer | 1.2yrs | US$5.80m | 0.13% $ 618.5k | |
Executive VP of Research & Development and Chief Medical Officer | 1.4yrs | US$8.13m | 0.018% $ 89.2k | |
Executive VP & CFO | less than a year | no data | 0.17% $ 803.9k | |
Senior VP | no data | no data | no data | |
Senior VP | less than a year | no data | 0% $ 0 | |
Chief People Officer | 2.1yrs | no data | no data | |
Executive VP | 1.4yrs | no data | no data | |
Senior Vice President of Finance | no data | no data | 0.043% $ 207.1k | |
Secretary | no data | no data | no data |
1.3yrs
Average Tenure
58.5yo
Average Age
Experienced Management: ALLO's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Members
Name | Position | Tenure | Compensation | Ownership |
---|---|---|---|---|
Co-Founder & Executive Chairman | 6.6yrs | US$9.36m | 2.94% $ 14.3m | |
Co-Founder | 6yrs | US$14.06m | 3.7% $ 18.0m | |
Co-Founder & Director | 6.6yrs | US$684.49k | 0.15% $ 706.2k | |
Lead Independent Director | 6.2yrs | no data | no data | |
Independent Director | 6.2yrs | US$585.00k | 0.15% $ 738.0k | |
Independent Director | 6.2yrs | US$510.00k | 0.12% $ 595.4k | |
Independent Director | 6.2yrs | no data | no data | |
Independent Director | 5.8yrs | US$495.00k | 0.080% $ 388.5k | |
Member of Scientific Advisory Board | no data | no data | no data | |
Member of Scientific Advisory Board | no data | no data | no data | |
Chairman of Scientific Advisory Board | no data | no data | no data | |
Independent Director | 6.2yrs | no data | no data |
6.2yrs
Average Tenure
65yo
Average Age
Experienced Board: ALLO's board of directors are considered experienced (6.2 years average tenure).